Medpace Faces Securities Class Action Over Backlog Disclosures

Overview

• A federal class action titled Durbin v. Medpace is pending in the U.S. District Court for the Southern District of Ohio and accuses the company of misleading investors about backlog cancellations.
• The complaint says Medpace repeatedly called cancellations “well behaved” while its fourth-quarter 2025 book-to-bill fell to 1.04 after the Feb. 9, 2026 results and the stock dropped roughly 15.9% the next day.
• Some plaintiff counsel report developing facts that cancellations worsened into first-quarter 2026 and that President Jesse Geiger announced his intention to resign, items they say coincided with an April 23 intraday share decline.
• Multiple plaintiff firms including Rosen, Faruqi, Pomerantz, Bleichmar Fonti & Auld and others are soliciting Medpace investors to seek lead-plaintiff status with a firm deadline of June 8, 2026.
• If a lead plaintiff is appointed the case could push document discovery, force testimony from executives, and affect shareholder recoveries and how investors view Medpace’s forward guidance.